Citations

Clear

27 citation(s) found for "Javaid, M K".

Global Burden of Elevated LDL-C
Collaborators, GBD 2023 LDL Cholesterol, Razo, Christian, DeCleene, Nicole K., Johnson, Catherine O., Stark, Benjamin, LeGrand, Kate, Aalruz, Hasan, Abaraogu, Ukachukwu O., Abdelnabi, Mahmoud, Abd-Elsalam, Sherief, Abdelwahab, Siddig Ibrahim, Abdollahi, Arash, Abdrabou, Mostafa M., Abdul‐Rahman, Toufik , Getahun, Habtamu Abebe, Abiodun, Olumide, Abohashem, Shady, Abonie, Ulric Sena , Abourashed, Nagah M , Abramov, Dmitry, Abrar, Mohammed Mehdi, Farha, Rana Kamal Abu, Abubakar, Bilyaminu, Aburuz, Salahdein, Abushanab, Dina, Adams, Lisa C., Adamu, Nuhu Lawan Lawan, Adegbile, Oluwatobi E , Adegoke, Nurudeen A., Adekola, Saheed Ayodeji, Adeleke, Olumide Thomas , Adesina, Miracle Ayomikun, Afoakwah, Clifford, Afolabi, Aanuoluwapo Adeyimika, Afrashteh, Fatemeh , Afrifa-Yamoah, Ebenezer, Agyemang‐Duah, Williams , Ahmad, Suhaib, Ahmed, Asma , Ahmed, Gasha Salih, Ahmed, Luai A., Ahmed, Mehrunnisha Sharif, Ahmed, Meqdad Saleh , Ahmed, M. , Ahmed, Mushood, Ahmed, Syed Anees, Ahmed, Zohra, Aiyer, Aishwarya, Ajami, Marjan, Akalanka, Kasuni H.M. , Akhtar, Muhammad Nadeem, Akrami, Ashley E, Akyea, Ralph Kwame, Hasan, Syed Mahfuz Al , Zoubi, Mohammad Ahmmad Mahmoud Al, Alahdab, Fares , Al-Ahmad, Mohammad M. , Alajajian, Stephen , Alajlani, Muaaz , Alalwan, Tariq A., Al-Amri, Issa Sulaiman, Alanzi, Turki M., Alarifi, Abdullah, Al-Azzam, Sayer, Albashtawy, Mohammed, Al-Dewik, Nader, Algahtani, Fahad D., Algammal, Abdelazeem M, Alhalaiqa, Fadwa Naji, Ali, Mohammad Daud , Ali, Mohammed Usman, Ali, Rafat, Ali, Syed Shujait, AL-Iede, Montaha, Alipour, Morteza, Al-Jabi, Samah W., Alkhatib, Mayson H. , Allawi, Raad Hatim , Allemailem, Khaled S. , (6837737), Mohammed Z. Allouh, Almahmeed, Wael, Al-Marwani, Sabah , Almazan, Joseph Uy, Alnaeem, Mohmmad Minwer, Alotaibi, Haifa F. F., Alqahtani, Saleh A, Alqudah, Mohammad , Alqudimat, Mohammad R, Al-Qudimat, Ahmad Rajeh, Alrimawi, Intima , Alrousan, Sahel Majed, Alshahrani, Najim Z., Altaany, Zaid, Altaf, Awais, Althobiani, Malik A., Altwalbeh, Diala, Al-Worafi, Yaser Mohammed, Aly, Hany, Alzoubi, Karem H., Al-Zubairi, Adel S., Amafah, Joy, Mohammadi, Masoud Aman, Amini, Saeed, Amini-Salehi, Ehsan, Ananda, Roshan A., Ancuceanu, Robert, Anil, Abhishek, Anjana, Prapti, Anuoluwa, Boluwatife Stephen, Anvari, Saeid, Anwar, Sumadi Lukman, Anyasodor, Anayochukwu Edward , Appati, Walter, Arafa, Elshaimaa A , Aravkin, Aleksandr Y. , Areda, Demelash, Aregawi, Brhane Berhe, Torre, Jorge Arias de la, Arruda, Gustavo Aires , Asghari-Jafarabadi, Mohammad , Ashraf, Saad , Asare, Bernard Yeboah‐Asiamah , Atac, Omer, Athari, Seyyed Shamsadin, Atorkey, Prince , Aurangzeb, Khursheed, Awan, Usman Ayub , Awol, Kemal Lemnuro Lemnuro, Ayala, Camila Ospina , Ayli, Berrak Itir, Azad, A.K.M., Azzam, Ahmed Y., Babiker, Rasha, Badar, Muhammad, Badran, Alaa Aboelnour, Baghlaf, Khlood K., Balabekova, Marina, Balakrishnan, Senthilkumar , Baltatu, Ovidiu Constantin , Banach, Maciej, Bashir, Muhammad Irfan , Bashir, Shahid, Bashiri, Azadeh, Bastan, Mohammad-Mahdi, Bayat, Mahdis , Behera, Surama Manjari , Belayneh, Melesse, Bello, Abdulrahman Babatunde , Belo, Luís, Bhaskar, Sonu, Bizzozero-Peroni, Bruno, Bogale, Sitotaw Kerie, Bolourinejad, Paria , Bonny, Aimé , Carvajal, Alejandro Botero, Bouaoud, Souad, Britton, Gabrielle, Bustanji, Yasser, Butt, Zahid A., Cao, Yu, Catapano, Alberico L., Cegolon, Luca, Cembranel, Francieli , Chadwick, Joshua , Chau, Lam Duc, Chaudhary, Anis Ahmad, Chen, An-Tian, Chen, Hana, Chen, Haowei , Cheng, Haojin, Cheung, Ka Ching , Chew, Nicholas WS, Chi, Gerald, Cho, William C. S., Chong, Bryan, Chopra, Deepti, Chopra, Shivani , Cicero, Arrigo Francesco Giuseppe, Criqui, Michael H., Cruz-Martins, Natalia, Dahabiyeh, Lina, Khatri, Bishal Dahal , Dalakoti, Mayank, D’Amico, Emanuele, Damtie, Endalamaw Tesfa, Dandona, Lalit , Dandona, Rakhi, D’Anna, Lucio , Danpanichkul, Pojsakorn, Dardas, Latefa Ali , Das, Sayan Kumar, Davletov, Dimash, Dergaa, Ismail, Derseh, Hunegnaw Almaw , Desale, Aragaw Tesfaw, Devanbu, Vinoth Gnana Chellaiyan, Devegowda, Devananda, Dewan, Syed Masudur Rahman, Dhali, Arkadeep , Dhungel, Bibha, Silva, Diana Dias da, Didehvar, Kimia, Ding, Xueting, Do, Thanh Chi, Do, Thao Huynh Phuong, Dohare, Sushil, Dong, Dachuan, D’Oria, Mario, Dorostkar, Fariba, Doshi, Ojas Prakashbhai, Dresse, Menayit Tamrat , Du, Mi, Ebraheim, Lamiaa Labieb Mahmoud, Edeh, Cynthia , Eftekhari, Behrad, Sedeh, Ashkan Eighaei , Ekholuenetale, Michael , Arab, Rabie Adel El , Eldaboush, Ahmed, El-Dahiyat, Faris , Elhoumed, Mohamed, Elmeligy, Omar Abdelsadek Abdou, Elmonem, Mohamed A., Elmoselhi, Adel B., Elnaem, Mohamed Hassan , Eltahawy, Abdelgawad Salah, Etaee, Farshid, Fakhradiyev, Ildar , Fakorede, Sodiq, Farasani, Abdullah , Fareed, Mohammad , Farhana, Aisha, Faris, MoezAlIslam Ezzat Mahmoud, Farsi, Farima , Fatima, Zareen, Fazylov, Timur, Fekadu, Ginenus , Ferreira, Nuno, Fischer, Florian, Fonzo, Marco , Gadanya, Muktar A., Galali, Yaseen, Ganesh, Balasubramanian , Gangachannaiah, Shivaprakash, Gao, Dingwei, Garcia-Azorin, David, Garg, Paarth, Gautam, Rupesh K., Gaye, Bamba , Gebresilassie, Mizan Habtemichael, Gete, Kalab Yigermal , Ghadirian, Fataneh, Ghaffari, Kazem , Ghamkhar, Arin, Gharaibeh, Lobna, Ghasemi, Mohammadreza, Ghimire, Sailaja, Gil, Artyom Urievich, Gilani, Syed Abdullah , Gohari, Kimiya, Gohil, Megha Nishith , Golechha, Mahaveer, Goleij, Pouya , Golmohammadi, Melika , Goyal, Aman, Grada, Ayman, Grover, Ashna , Gu, Long, Gufue, Zenawi Hagos , Guo, Zheng, Gupta, Sapna , Gurgoglione, Filippo Luca, Haghtalab, Arian, Nam, Nguyen Hai, Hailu, Kirubel Tesfaye , Halder, Pritam, Hamdy, Nadia M., Hamidi, Hossein , Hamidi, Samer, Hamoudi, Rifat, Harsini, Sara, Hasnain, Md Saquib , Hassan, Ikrama, Hassan, Nageeb, Hassan, Treska S , Ahmed, Omed Hassan , Hebert, Jeffrey J., Helmy, Yosra A. , Hiraike, Yuta, Holla, Ramesh, Hoseinzadeh, Mehdi, Hostiuc, Mihaela , Hostiuc, Sorin, Hotwani, Priya, Hu, Yifei, Huang, Junjie, Huang, Yu-Song, Hushmandi, Kiavash, Hussein, Dursa, Hussein, Mohammed Asif , Ibrahim, Ismail A., Ibrayeva, Anel, Ikiroma, Adalia , Ikram, Jibran, Ilic, Irena M., Imam, Mohammad Tarique , Imani, Masoud, Imodoye, Sikiru Opeyemi, Imoh, Lucius Chidiebere , Ionescu, Andreea Iuliana, Ionescu, Radu Tudor, Iqhrammullah, Muhammad, Ishaqui, Azfar Athar, Islek, Duygu , ISMAIL, NAHLAH ELKUDSSIAH, Ismoldayev, Yerlan, Iwagami, Masao , Iyer, Mahalaxmi, Izquierdo-Condoy, Juan S.S., Jafari-Khounigh, Ali , Jahanshahi, Ali, Jahrami, Haitham , Jakovljevic, Mihajlo, Jamal, Armaan, Jamali, Navid, Jamaluddin, Jazlan , Jamshidi, Masoud, Jansen, Robin , Jarrahi, Esmaeil , Javaid, Syed Sarmad , Jawaid, Talha, JEBASINGH, FELIX, Jemal, Mohammed, Ji, Zixiang , Jibat, Nathan T., Jin, Wenyi , Jokar, Mohammad, Joseph, Nitin, Raj, Jesu Vijay Sheldon Joseph Michael, Joshi, Krupal, Joshua, Charity Ehimwenma, Jung, Sang-Hyuk, K, Vaishali, Kadir, Dler Hussein , Kahe, Farima, Kalani, Rizwan, Kalra, Sanjay, Kamenova, Saltanat, Kamorudeen, Ramat T., Kamyshnyi, Oleksandr, Kansal, Subham, Kantar, Rami S., Kar, Debasish , Karakasis, Paschalis, Karimi, Aliasghar, Behnagh, Arman Karimi , Karun, Sadanand , Kazemian, Sina, Kesse-Guyot, Emmanuelle, Khaleel, Anas, Khalid, Nauman, Khalid, Sidra, Khalil, Anees Ahmed , Khan, Ajmal, Khan, Md Abdullah Saeed, Khan, Moien AB, Khan, Muhammad Hamza , Khan, Serab, Khan, Sumaiya, Khan, Yusuf S. , Kheirallah, Khalid A, Khoshvaght, Samira, Khosravi, Sepehr, Kim, Hye Jun, Kim, Kwanghyun, Kisa, Adnan, Kishore, Ladli, Kokkorakis, Michail, Kondybayeva, Aida, Krishan, Kewal, Kua, Chong-Han, Kuddus, Mohammed, Kulimbet, Mukhtar , Kulkarni, Vishnutheertha, Kumar, Dewesh , Kumar, Nitesh, Kumar, Sanjay Kirshan, Kunutsor, Setor K., Kurpad, Krishna Prasad , Kusuma, Dian, Lahariya, Chandrakant, Lai, Daphne Teck Ching , Lai, Hanpeng , Lajunen, Timo, Lakanova, Balzhan, Lallukka, Tea, Larsson, Anders O., Le, Duc Tin , Le, Thao T. , Le, Thoa, Le, Trang Thi Bich , Ledda, Caterina, Lee, Hayeon, Lee, Sang-woong, Lee, Sergey Vadimovich, Lee, Seung Won, Leivaditis, Vasileios, Lema, Gebretsadik Kiros , Lemma, Dawit Alemu, Lenjisa, Jimma, Lewis, Mitchelle Shilpa , Li, Chengfeng , Li, Xingang , Li, Yongze, Lim, Lee-Ling, Lindholm, Daniel , Liu, Haipeng , Liu, Xianliang, Liu, Xuefeng, Liu, Yubo, Livingstone, Katherine M., Llanaj, Erand , Lokunarangoda, Niroshan Chandrajith, López-Gil, José Francisco, Lui, Pauline Po Yee, Luo, Peng, Lv, Lei, Lytvyak, Ellina, Ma, Kevin Sheng-Kai, Mabrok, Mahmoud, Machoy-Rakoczy, Monika , Madinehzad, Seyed Ataollah , Maffia, Pasquale, Gomez, Javier A. Magaña, Mahmood, Nozad Hussein, Malik, Md. Zubbair, Malta, Deborah Carvalho, MAMAND, DOSTE RASHID, Maniya, Muhammad Talha, Mansoor, Farheen, Mansourian, Marjan, Manzoor, Shaista, Marghani, Basma Hamed, Martinez-Piedra, Ramon, Martini, Santi, Martorell, Miquel, März, Winfried, Marzouk, Sammer, Masi, Stefano, Masrouri, Soroush , Maude, Richard J. , Mavrovounis, Georgios, McPhail, Steven M., Mendoza, Walter, Menezes, Ritesh G., Mengistie, Emiru Ayalew, Menon, Tara P., Mestrovic, Tomislav, Mettananda, Chamila Dinushi Kukulege, Metwally, Mohamed M.M., Jonasson, Junmei Miao , Mikrajab, Muhammad Agus Naufal, Minhas, Abdul Mannan Khan, Mirrakhimov, Erkin M., Mitra, Sayan , Mitra, Tridip, Modi, Dhruti, Mohamed, Mona Gamal, Ahmed, Khabab Abbasher Hussien Mohamed, Mohammad, Ameen Mosa , Mohammadi, Saeed, Mohammed, Omer, Mohan, Syam , Molla, Tewodros Shibabaw, Molokhia, Mariam, Moni, Mohammad Ali, Namin, Sara Montazeri , Morovvati, Mahdis, Heris, Reza Mosaddeghi, Motappa, Rohith, Mousavi, Seyed Ahmad , Kiasary, Seyed Mohamad Sadegh Mousavi, Yousefi, Kimia Mozahheb , Mubarik, Sumaira, Munkhsaikhan, Yanjinlkham, Musa, Sani, Mwita, Julius C., Nabipoorashrafi, SeyedAli, Nagarajan, Ahamarshan Jayaraman , Naik, Ganesh R., Naik, Hiten, Nainu, Firzan, Nartey, Yvonne , Nassar, Mahmoud, Natto, Zuhair S., Naureen, Zakira, Nawaiseh, Hala Khaled, Nayak, Biswa Prakash, Nayak, Vinod C., Nazari, Mojdeh, Ndakotsu, Andrew , Nega, Amanuel Tebabal , Nega, Mulata H., Negash, Abigia Ashenafi, Negoi, Ionut, Nguyễn, Cao Duy, Nguyen, Cuong Tat , Nguyen, Hau Thi Hien, Nguyen, Nghia Phu , Nguyen, Phat Tuan , Nguyen, Van Thanh, Niazi, Robina Khan, Nomura, Shuhei , Noreen, Mamoona , Nawsherwan, Noubiap, Jean Jacques, Nugen, Fred, Nur, Aqsha, Odediji, Saheed Adeyinka, Ogunmodede, O.S., Ojedoyin, Olusegun Olatunji , Ojo, Oluwafemi Adeleke , Okati-Aliabad, Hassan, Oliveira, Gláucia Maria Moraes, Olorukooba, Abdulhakeem Abayomi, Ong, Qi Chwen, Orru, H, Ortiz, A., Ortiz-Prado, Esteban, Osborne, Augustus, Osei, George Nkrumah , Ostrominski, John W. , Oumer, Abdu, Ouyahia, Amel, Owolabi, Mayowa O., Oyebola, Kolapo, Ozsahin, Ilker, Anand, Mahesh Padukudru, Palicz, Tamás , Panda, Sujogya Kumar , Pandi-Perumal, Seithikurippu R., Panos, Georgios D., Papadimopoulos, Ilias, Parija, Pragyan Paramita , Parikh, Romil R., Pascucci, Eleonora, Pasovic, Maja , Passera, Roberto, Patel, Mitesh, Patel, Niki Rut, Patel, Satyananda, Patil, Ashlesh, Patil, Shankargouda, Patoulias, Dimitrios, Pattnaik, Snigdha, Toroudi, Hamidreza Pazoki, Pekarcikova, Jarmila, Peprah, Prince, Pereira, Gavin, Pirera, Edoardo , Plotnikov, Evgenii, Poluru, Ramesh, Prasad, Manya, Prashant, Akila, Prates, Elton Junio Sady, Pugliese, Nicola Riccardo, Puvvula, Jagadeesh, Qi, Xiang, Qureshi, Ali, Radhakrishnan, Venkatraman, Raghav, Pankaja, Raghav, Yashpal Singh Raghav, Raghuveer, Pracheth , Rahim, Fakher , Rahim, Hawbash Mohammed-Amin, Rahimi, Sajjad, Rahman, Fryad Majeed, Rahman, M Sajjadur , Rahman, Mohammad Hifz Ur, Rahman, Mosiur, Rajendran, Judah, Rajput, Prashant, Ramasamy, Chitra, Ramasamy, Shakthi Kumaran, Rao, Asad Gul , Rao, Mithun , Rao, Sowmya J, Rasouli-Saravani, Ashkan, Rath, Shree, Rathi, Isha, Rawaf, David Laith , Rawaf, Salman, Reddy, Murali Mohan Rama Krishna, Rezaei, Mina, Rezaei, Nazila, Rezaeian, Mohsen , Rodriguez, Jefferson Antonio Buendia, Roever, Leonardo, Ross, Allen Guy Patrick, Rubeshkumar, Polani, Rwegerera, Godfrey Mutashambara , Saad, Aly M. A., Sabet, Cameron John, Sadarangani, Kabir P., Rafiei, Seyed Kiarash Sadat, Sadeghi, Ehsan, Sadeghi, Erfan, Sadeghi, Masoumeh, Sadek, Bassem, Sadek, Mustafa, Sadr, Hossein, Saeb, Mohammad Reza, Saeed, Umar, Saeedi, Maryam , Safiullah, Muhammad , Sahebkar, Amirhossein, Sajadi, S Mohammad, Saleh, Mohamed A., Salehi, Mahdi , Salimi, Sohrab, Samargandy, Saad, Samy, Abdallah M., Saravanan, Aswini , Sarfo, Jacob Owusu, Sarode, Gargi Sachin, Sarode, Sachin C., Sathian, Brijesh, Far, Mehrdad Savabi, Schlaich, Markus P., Schuermans, Art, Sejben, Anita, Semreen, Mohammad H., Senol, Yigit Can, Sessa, Francesco, Sewor, Christian , Seylani, Allen, Shahrahmani, Fatemeh, Shahwan, Moyad Jamal, Sham, Sunder, Shan, Dan, Sharifan, Amin , Sharma, Kamal, Sharma, Ravi Kumar, Sharma, Ujjawal , Shehzadi, Somia , Shetty, Mahabalesh, Shetty, Pavanchand H, Shi, Fanchao , Shi, Huizhong , Shi, Yongfeng, Shiri, Rahman , Shittu, Aminu, Shiue, Ivy, Shoaib, Ambreen, Shool, Sina, Shorofi, Seyed Afshin, Shuval, Kerem, Sia, Ching-Hui, Silva, Luís Manuel Lopes Rodrigues, Singh, Amit, Singh, Baljinder, Singh, Harmanjit, Singh, Harpreet, Singh, Lucky, Singh, Paramdeep, Singh, Siddharth , Singh, Sunil Kumar, Singh, Surjit, Singh, Vanshika , Sinha, Mukesh Kumar, Skryabin, Valentin Yurievich, Sokhal, Balamrit Singh , Sood, Prashant , Soraneh, Soroush , Sorensen, Reed J D , Srivastav, Prateek , Stanikzai, Muhammad Haroon , Starodubova, Antonina V., Stubbs, Peter, Suhag, Alisha, Sulaiman, Sahabi K., Odidi, Muritala Suleiman, Sulistiyorini, Desy , Sun, Jing , Sun, Zhong, Szarpak, Lukasz, Ty, Sree Sudha, Damavandi, Payam Tabaee, Tabatabaei, Seyyed Mohammad, Tabatabai, Shima, Tagiisuran, Balamurugan, Ali, Eman Taha Osman, Soodejani, Moslem Taheri, Taiba, Jabeen, Tajabadi, Shima, Talic, Stella, Talukder, Ashis, Adugna, Dessalegn Tamiru, Tampa, Mircea, Tan, Jianye, Tanabayeva, Dariga, Tanashat, Mohammad , Tang, Jiahao , Tantisattamo, Ekamol, Tariq, Saba, Temsah, Reem, Teramoto, Masayuki, Tesfamariam, Wegen Beyene , Tewari, Jay , Thakar, Vidhi, Thangavelu, Lakshmi, Tharwat, Ismaeel, Thiruvengadam, Muthu , Thomas, Nikhil Kenny, Ticoalu, Jansje Henny Vera, Tiwari, Krishna, Tleshev, Madi, Tonelli, Marcello, Topór-Mądry, Roman , Touvier, Mathilde, Tovani-Palone, Marcos Roberto, Tran, An Thien, Tran, Thang Huu, Duc, Nguyen Tran Minh , Tricò, Domenico , Tse, Gary, Tseriotis, Vasilis-Spyridon, Tualeka, Abdul Rohim , Tye, Sok Cin , Ullah, Riaz, Umair, Muhammad, Umar, Lawan , Ozsahin, Dilber Uzun, Uzunçıbuk, Hande, Vaithinathan, Asokan Govindaraj , Vakili, Omid , Eynde, Jef Van den, Varghese, Joe, Vellingiri, Balachandar, Verma, Poonam, Villalobos-Daniel, Victor E., Vlassov, Vasily, Wang, Nelson, Wang, Qingzhi, Wang, Wanzhou, Wang, Wei, Wang, Yanzhong, Wang, Zhihua, Wani, Tanveer A.A., Wei, Melissa Y., Weintraub, Robert G., Wibowo, Yohanes Cakrapradipta, Wickramasinghe, Dakshitha Praneeth, Wickramasinghe, Nuwan Darshana, Witts, William Kwame , Wonde, Tewodros Eshete , Wongsin, Utoomporn , Wu, Peng, Xiao, Guangqin, Xie, Wanqing , Xu, Suowen, Xu, Wanqing, Yadav, Vikas , Yahoo, Saba, Yang, Hanwen, Yano, Yuichiro , Yao, Haiqiang , Yarahmadi, Amir, Yin, Dehui , Yismaw, Yazachew Engida, Yon, Dong Keon, Yu, Chuanhua, Yu, Elaine A., Yu, Hairui , Yu, Yong , Yuan, Quan, Zafar, Mubashir , Zaghampour, Manijeh, Zamora, Nelson, Zanghì, Aurora , Zargar, Seema , Zeariya, Mohammed G M, Zeru, Eyael M, Zhang, Beijian, Zhang, Hanyu, Zhang, Julio Min Fei, Zhang, Yunquan, Zhang, Zhichang, Zhanuzakov, Murat , Zhao, Zhongyi, Zheng, Ming‐Hua , Zhong, Anthony , Zhong, Claire Chenwen, Zhou, Hao, Zhou, Jiayan, Zhou, Xiao-Dong, Zhu, Zhengyang , Zhumagaliuly, Abzal, Zitoun, Osama A. , Zoghi, Ghazal , Zoromba, Mohamed Ali, Zumla, Alimuddin, Zyoud, Sa’ed H., Hay, Simon I., Mokdad, Ali H., Murray, Christopher J. L., Roth, Gregory A., Sun, Zhong , Hay, Simon I , Roever, Leonardo , Krishan, Kewal , Moni, Mohammad Ali , Buendía, Jefferson Antonio , Badar, Muhammad , Wickramasinghe, Nuwan Darshana , Nassar, Mahmoud , Dewan, Syed Masudur Rahman , Naik, Ganesh R. , Wang, Yanzhong , Rath, Shree , Karakasis, Paschalis , Zheng, Ming-Hua , Taiba, Jabeen , Razo, Christian , DeCleene, Nicole K., LeGrand, Kate E , Abaraogu, Ukachukwu Okoroafor , ElHafeez, Samar Abd , Abdelmasseh, Michael , Abdelnabi, Mahmoud , Abd‐Elsalam, Sherief , Elshenawy, Rasha Abdelsalam , Abdelwahab, Siddig İbrahim , Abdolizadeh, Ali , Abdollahi, Arash, Abdoun, Meriem , Abdrabou, Mostafa M. , Abdulah, Deldar Morad , Abdullahi, Auwal , Shenkut, Melese, Abiodun, Olugbenga Olusola , Abiodun, Olumide A , Abohashem, Shady , Abtahi, Dariush , Farha, Rana Kamal Abu , Abubakar, Bilyaminu , Abuhelwa, Ahmad Y. , Abukhadijah, Hana J , Aburuz, Salahdein , Adamu, Nuhu Lawan , Adane, Mesafint Molla , Addo, Isaac Yeboah , Adedokun, Kamoru Ademola , Adekola, Saheed Ayodeji, Adesina, Miracle Ayomikun , Adisu, Molalign Aligaz , Adnan, Mohd , Afoakwah, Clifford , Afolabi, Aanuoluwapo Adeyimika, Afrifa‐Yamoah, Ebenezer , Afzal, Saira , Agordoh, Percival Delali , Ahmad, Aqeel , Ahmad, Khabir , Ahmad, Sajjad , Ahmed, Gasha Salih, Ahmed, Nesredin , Ajami, Marjan , Akhtar, Muhammad Nadeem , Akindele, Mukadas Oyeniran , Akkaif, Mohammed Ahmed , Akyea, Ralph Kwame , Zoubi, Mohammad Ahmmad Mahmoud Al, Alalwan, Tariq A. , Al‐Aly, Ziyad , Al-Amri, Issa Sulaiman , Alanzi, Turki Matar Khalaf, Al-Ashwal, Fahmi Y. , Al‐Azayzih, Ahmad , Al-Azzam, Sayer , Al-Bashaireh, Ahmad M. , ALBashtawy, Mohammed , Aleidi, Shereen M. , Algahtani, Fahad D. , AlHabib, Khalid F. , Ali, Abid , Ali, Asgar , Ali, Bassam R. , Al‐Iede, Montaha , Alif, Sheikh Mohammad , Alipour, Morteza, Al‐Jabi, Samah W. , Aljunid, Syed Mohamed , Alkubati, Sameer Abdulmalik , Almagharbeh, Wesam Taher , Almahmeed, Wael , Almazan, Joseph Uy , Alniss, Hasan Yaser , Alomari, Mahmoud A. , Alotaibi, Haifa F. , Alqahtani, Saleh A. , Alqudimat, Mohammad R. , Al-Qudimat, Ahmad Rajeh , Al‐Raddadi, Rajaa , Alsbou, Mohammed , Alshahrani, Najim Zafer , Al-Shami, Ali Salman , Altaf, Awais , Althobiani, Malik A , Alwafi, Hassan , Al‐Worafi, Yaser Mohammed , Aly, Hany Z. , Al‐Zalabani, Abdulmohsen H. , Alzoubi, Abdallah , Alzoubi, Karem Hasan , Amafah, Joy, Amin, Amr , Amini, Saeed, Amini‐Salehi, Ehsan , Amusa, Ganiyu , Ang, Song Peng , Anieto, Ebuka Miracle , Anil, Abhishek , Anjana, Dr. Prapti, Anvari, Saeid, Appati, Walter , Arabloo, Jalal , Arafat, Mosab , Areda, Demelash, Arefnezhad, Reza , Torre, Jorge Arias de la, Aripov, Timur , Arockiaraj, Jesu , Asdaq, Syed Mohammed Basheeruddin , Ashraf, Syed Amir , Ashraf, Tahira , Ataç, Ömer , Athar, Mohammad , Athari, Seyyed Shamsadin , Aurangzeb, Khursheed , Awan, Sana Javaid , Awol, Kemal Lemnuro, Awotidebe, Adedapo Wasiu , Aylı, Berrak Itır , Azarboo, Alireza , Aziz, Sadat Abdulla , Azzolino, Domenico , Babu, Abraham Samuel , Babu, Giridhara R. , Badiye, Ashish , Baghlaf, Khlood K , Baig, Atif Amin , Bakhshali, Mohamad Amin , Banach, Maciej , Banik, Palash Chandra , Barqawi, Hiba Jawdat , Barrow, Amadou , Barua, Lingkan , Bashir, Shahid , Bashiri, Azadeh , Bastan, Mohammad‐Mahdi , Bayih, Mulat Tirfie , Beeraka, Narasimha Murthy , Begum, Tahmina , Behera, Priyamadhaba , Behnam, Babak , Ramírez, Diana Fernanda Bejarano , Belo, Luı́s , Berihun, Abiye Assefa , Bhattacharjee, Priyadarshini , Bhatti, Gurjit Kaur , Bhatti, Jasvinder Singh , Biswas, Atanu , Biswas, Bijit , Bizzozero‐Peroni, Bruno , Bodur, Mahmut , Bogale, Sitotaw Kerie , Bohn, Lucimére , Boloor, Archith , Carvajal, Alejandro Botero , Boudalia, Sofiane , Bugiardini, Raffaele , Busch, Felix , Bustanji, Yasser, Campos, Luciana Aparecida , Catapano, Alberico Luigi , Cegolon, Luca , Cenko, Edina , Cerin, Ester , Chakraborty, Chiranjib , Chandika, Rama Mohan , Chandrasekar, Eeshwar K , Chandrasekaran, Baskaran , Chattu, Vijay Kumar , Chaudhary, Anis Ahmad , Chaudhuri, Sirshendu , Cheema, Asad Ali Ahmed , Chichagi, Fatemeh , Ching, Patrick R , Cho, William C.S., Choi, Dong‐Woo , Chong, Bryan , Chopra, Deepti , Chopra, Hitesh , Choudhari, Sonali Gajanan , Chu, Dinh‐Toi , Chukwu, Chidozie Williams , Chung, Sheng‐Chia , Chung, S. Y. , Cicero, Arrigo F.G. , Cosma, Claudia , Criqui, Michael H. , Dadras, Omid , Dai, Xiaochen , Dai, Zhaoli , Dalakoti, Mayank , D’Amico, Emanuele , Tesfa, Endalamaw , Danpanichkul, Pojsakorn , Darcho, Samuel Demissie , Davletov, Dimash , Davletov, Kairat , Dejenie, Tadesse Asmamaw , Bo’, Cristian Del , Delgado‐Enciso, Iván , Denova‐Gutiérrez, Edgar , Dergaa, Ismail , Dervišević, Emina , Devegowda, Devananda , Dewan, Syed Masudur Rahman , Dhimal, Meghnath , Dhungel, Bibha , Do, Thanh Chi, Phuong, Thao Huynh, Doshi, Ojas Prakashbhai , Doshi, Rajkumar , Dourado, Paulo Magno Martins , Dowou, Robert Kokou , Du, Mi , Duncan, Bruce Bartholow , Durães, André Rodrigues , Ebohon, Osamudiamen , Eftekhari, Behrad , Eladl, Mohamed Ahmed , Eldaboush, Ahmed , Elgendy, Islam Y. , Elhadi, Muhammed , El‐Huneidi, Waseem , Elmonem, Mohamed A. , Elmoselhi, Adel B. , Fabin, Natalia , Fadaka, Adewale Oluwaseun , Fagbamigbe, Adeniyi Francis , Fakorede, Sodiq , Fatima, Zareen , Fayaz, Mohammad , Fazylov, Timur, Fernández‐Jiménez, Rodrigo , Fischer, Florian, Fogacci, Federica , Foschi, Matteo , Gadanya, Muktar A., Gajdács, Márió , Galali, Yaseen , Ganesan, Balasankar , Gangachannaiah, Shivaprakash , Gašević, Danijela , Habtemichael, Mizan , Getacher, Lemma , Jolfayi, Amir Ghaffari , Ghamkhar, Arin, Ghazy, Ramy Mohamed , Ghimire, Sailaja, Ghith, Nermin , Gil, Artyom , Gill, Paramjit Singh , Gnedovskaya, Elena V. , Goh, Lay Hoon , Gohari, Kimiya, Golechha, Mahaveer , Goulart, Alessandra C. , Goyal, Aman , Grada, Ayman , Gu, Long , Gubari, Mohammed Ibrahim Mohialdeen , Guha, Avirup , Gunawardane, Damitha Asanga , Gupta, Rajeev , Gurgoglione, Filippo Luca , Guzmán-Esquivel, José , Guzmán-Muñoz, Eduardo , Haghtalab, Arian , Halder, Pritam , Hamdy, Nadia Μ. , Hammad, Eman A. , Hanif, Asif , Hanifi, Nasrin , Hankey, Graeme J. , Harsini, Sara , Hartmann, Phillipp , Hasan, Ikramul , Hashempur, Mohammad Hashem , Hassan, Amr , Hassan, Ibrahim Nagmeldin , Hayat, Khezar , Hezam, Kamal , Hiraike, Yuta , Holla, Ramesh , Hostiuc, Sorin , Htay, Mila Nu Nu , Huang, Junjie, Hushmandi, Kiavash , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ibrahim, Khalid S. , Ibrayeva, Anel , Ikram, Jibran, Ilesanmi, Olayinka Stephen , Ilić, Irena , Ilić, Milena , Imodoye, Sikiru O. , Inbaraj, Leeberk Raja , Ionescu, Radu Tudor, Iqhrammullah, Muhammad , Irham, Lalu Muhammad , Ishaqui, Azfar Athar , Ismail, Nahlah Elkudssiah , Ismoldayev, Yerlan, Isola, Gaetano , Izquierdo‐Condoy, Juan S. , Jacob, Jaison , Jahanshahi, Ali , Jamal, Armaan , Jamali, Navid , James, Jerin , Jamshidi, Masoud , Jawaid, Talha, Jayasinghe, Yovanthi Anurangi , Jemal, Mohammed , Jeong, Seogsong , Jeswani, Bijay Mukesh , Jibat, Nathan Tolemariam , Jokar, Mohammad , Joó, Tamás , Joseph, Akaninyene Paul , Joseph, Mickaël Antoine , Joseph, Nitin , Joshi, Krupal , Jürisson, Mikk , K, Vaishali , Kakkar, Ashish Kumar , Kalani, Rizwan , Kalavani, Khalil , Kalra, Sanjay , Kamorudeen, Ramat T. , Kamyshnyi, Oleksandr , Kanaan, Saddam Fuad , Kanmodi, Kehinde Kazeem , Kantar, Rami S. , Kapoor, Neeti , Karajizadeh, Mehrdad , Karakasis, Paschalis , Karasneh, Reema A. , Kashoo, Faizan , Kashyap, Manoj Kumar , Kausar, Mohd Adnan , Kazemian, Sina , Kebede, Yabets Tesfaye , Kesse‐Guyot, Emmanuelle , Khademi, Reza , Khader, Yousef , Khajuria, Himanshu , Khaleel, Anas , Khalid, Sidra , Khalili, Anita , Khalili, Pantea , Khan, Maseer , Khan, Mohammad Idreesh , Khasbage, Sameer Uttamaro , Khatatbeh, Moawiah Mohammad , Khosla, Pavan , Khosravi, Sepehr , Kimokoti, Ruth W , Kısa, Adnan , Kishore, Ladli , Kivimäki, Mika , Kokkorakis, Michail , Kolahi, Ali‐Asghar , Kompani, Farzad , Kondybayeva, Аida , Korzh, Oleksii , Kostev, Karel , Laxminarayana, Sindhura Lakshmi Koulmane , Kua, Chong-Han , Kuddus, Mohammed , Kumar, Chandan , Kumar, G Anil , Kumar, Jogender , Kumar, Laksh , Kundu, Amartya , Kundu, Satyajit , Kunutsor, Setor K. , Kurniasari, Maria Dyah , Kytö, Ville , Lahariya, Chandrakant , Lakanova, Balzhan, Lantos, Tamás , Larebo, Yilma Markos , Lasrado, Savita , Lee�, HwaMin , Lee, Wei‐Chen , Leivaditis, Vasileios , Lenjisa, Jimma Likisa , Li, Ming‐Chieh , Li, Qiang , Li, Shaojie , Lim, Lee-Ling , Lodhi, Madeeha Shahzad , Lokunarangoda, Niroshan Chandrajith , López-Gil, José Francisco , Lorkowski, Stefan , Lucchetti, Giancarlo , Lui, Pauline Po Yee , Lv, Lei , Lytvyak, Ellina , Amin, Hawraz Ibrahim M. , Maffia, Pasquale , Magaña‐Gómez, Javier A. , Mahalleh, Mehrdad , Malik, Ahmad Azam , Malik, Tabarak , Malta, Déborah Carvalho , Mamand, Doste R. , Maniya, Muhammad Talha , Mannethodi, Kamaruddeen , Mansoor, Farheen, Mansourian, Marjan , Maqsood, Kaleem , Marateb, Hamid Reza , Marghani, Basma H. , Marino, Mirko , Martínez, Ramón , Martini, Daniela , Martini, Santi , Martorell, Miquel , März, Winfried , Marzouk, Sammer , Masi, Stefano , Mathur, Neeta , Matozinhos, Fernanda Penido , Mattiello, Rita , Mavrovounis, Georgios , McPhail, Steven , Mehto, Subhash , Meles, Hadush Negash , Menezes, Godfred Antony , Menon, Tara Pattilachan, Mensah, George A. , Merlino, Giovanni , Meštrović, Tomislav , Mettananda, Chamila Dinushi Kukulege , Mettananda, Sachith , Metwally, Mohamed M M, Mikrajab, Muhammad Agus, Minhas, Abdul Mannan Khan , Mittal, Madhukar , Mohamed, Nouh Saad , Ahmed, Khabab Abbasher Hussien Mohamed , Mohammad, Taj , Mohammadi, Abbas , Mohammadi, Mokhtar , Mohammadian-Hafshejani, Abdollah , Mohsen, Yazan , Shibabaw, Tewodros , Molokhia, Mariam , Monazzami, Amirabbas , Ghalibaf, AmirAli Moodi , Morovvati, Mahdis, Motappa, Rohith , Mozafar, Mehrdad , Mubarik, Sumaira , Muhammad, Jibran Sualeh , Munkhsaikhan, Yanjinlkham, Munshi, Anjana , Musa, Sani , Muthu, Sathish , Mwita, Julius Chacha , Myung, Woojae , Nainu, Firzan , Nargus, Shumaila , Nasrollahizadeh, Amir , Nassar, Mahmoud, Nauman, Javaid , Navaratna, Samidi Nirasha Kumari , Nawaiseh, Hala K. , Nayak, Biswa Prakash, Nega, Mulata Haile , Negash, Abigia Ashenafi , Negoi, Ionuţ , Abadi, Reza Nejad Shahrokh , Nematollahi, Mohammad Hadi , Nieddu, Luciano , Nketia, Richmond , Noubiap, Jean Jacques , Nri-Ezedi, Chisom Adaobi , Ntsekhe, Mpiko , Nugen, Fred , Oancea, Bogdan , Odat, Ramez M. , Oddi, Fabio Massimo , Oh, In‐Hwan , Okekunle, Akinkunmi Paul , Okonji, Osaretin Christabel , Olorukooba, Abdulhakeem Abayomi , Ong, Qi Chwen , Ordak, Michał , Orscelik, Atakan , Ortiz‐Prado, Esteban , Osuagwu, Uchechukwu Levi , Oumer, Abdu , Ouyahia, Amel , Özşahin, İlker , Padrón‐Monedero, Alicia , Padubidri, Jagadish Rao , Panos, Georgios D. , Papa, Mario Virgilio , Pardhan, Shahina , Passera, Roberto , Patel, Kunal Nitinkumar , Patel, Neel Navinkumar , Patel, Satyananda, Patil, Shankargouda, Patoulias, Dimitrios , Pattnaik, Snigdha, Toroudi, Hamidreza Pazoki, Pekarčíková, Jarmila , Peprah, Prince , Pereira, Gavin, Perico, Norberto , Perna, Simone , Petermann‐Rocha, Fanny , Pirnejad, Habibollah , Plotnikov, Evgenii, Poddighe, Dimitri , Poluru, Ramesh , Porntaveetus, Thantrira , Pradhan, Pranil Man Singh , Prasad, Manya , Prashant, Akila , Pugliese, Nicola Riccardo , Puvvula, Jagadeesh , Qiu, Jia-Yong , Radhakrishnan, Venkatraman, Raghav, Pankaja Raghav, Rahamon, Sheu Kadiri , Rahim, Hawbash Mohammed-Amin , Rahimi, Sajjad , Rahman, Muhammad Aziz , Raj, Jeffrey Pradeep , Raja, Adarsh , Rajendran, Judah , Rajput, Prashant , Ramadan, Mahmoud M. , Ramasamy, Chitra, Ramasamy, Shakthi Kumaran, Rashedi, Vahid , Rasouli‐Saravani, Ashkan , Rath, Shree , Rathi, Isha , Rathish, Devarajan , Rauniyar, Santosh Kumar , Rawassizadeh, Reza , Ray, Asit , Redwan, Elrashdy M , Rehman, Najeeb Ur , Remuzzi, Giuseppe , Rezaei, Nazila , Romadlon, Debby Syahru , Romoli, Michele , Rony, Moustaq Karim Khan , Ross, Allen Guy , Roy, Sharmistha , Roy, Shubhanjali , Russo, Michele , Saber-Ayad, Maha Mohamed , Sabet, Cameron John , Sadarangani, Kabir P. , Rafiei, Seyed Kiarash Sadat , Saddique, Muhammad Nabeel , Sadee, Bashdar Abuzed , Sadeghi, Masoumeh , Sadek, Bassem Shaban , Sadr, Hossein, Saeb, Mohammad Reza , Saeed, Mοhd , Saeedi, Maryam , Saghazadeh, Amene , Sagoe, Dominic , Sah, Ashok Kumar , Sharif‐Askari, Fatemeh Saheb , Sahebkar, Amirhossein , Sajadi, S. Mohammad, Sajid, Mirza Rizwan , Saki, Morteza , Sakshaug, Joseph W. , Salami, Afeez Abolarinwa , Saleem, Rahman Shah Zaib , Salihu, Abubakar Tijjani , Salimi, Sohrab , Samargandy, Saad J. , Samodra, Yoseph Leonardo , Samy, Abdallah M., Sarfo, Jacob Owusu , Sarmadi, Mohammad , Sarode, Gargi Sachin , Sassano, Michele , Sathian, Brijesh , Narayanan, Mukesh Kumar Sathya , Schlaich, Markus P. , Schuermans, Art , Schwarz, Ghil , Sejben, Anita , Selvaraj, Siddharthan , Semreen, Mohammad H. , Şenol, Yiğit Can , Şerban, Dragoş , Sethi, Yashendra , Setiawan, Christianus Heru , Shahid, Samiah , Shahini, Endrit , Shahrahmani, Fatemeh, Shahwan, Moyad Jamal , Shamim, Muhammad Aaqib , Shamsi, Anas , Shan, Dan, Shanawaz, Mohd , Shannawaz, Mohammed , Sharif, Nadim , Sharma, Bhoopesh Kumar , Sharma, Bunty, Sharma, Manoj , Sharma, Vishal , Shastry, Shamee , Sheidaei, Ali , Shenoy, Rekha R. , Shimels, Tariku , Shittu, Aminu , Shoaib, Ambreen , Shool, Sina , Shrestha, Sunil , Shuval, Kerem , Sia, Ching‐Hui , Siddig, Emmanuel Edwar , Siddiqi, Ahmed Kamal , Siddiqua, Ayesha , Silva, Diego Augusto Santos , Simkhada, Padam Prasad , Singh, Amit Kumar, Singh, Baljinder, Singh, Harpreet, Singh, Jasvinder A. , Singh, Lucky, Singh, Poornima Suryanath , Singh, Puneetpal , Sinha, Mukesh Kumar , Sinha, Ratnesh , Skryabin, Valentin Yurievich , Sorrentino, Michele , Spartalis, Michael , Stachteas, Panagiotis , Владимировна, Стародубова Антонина, Straube, Sebastian , Stubbs, Peter W. , Su, Chen‐Yang , Subramaniyan, Vetriselvan , Suhag, Alisha , Sulaieva, Oksana , Sun, Jing , Swain, Chandan Kumar , Szarpak, Łukasz , Y, Sree Sudha T, Damavandi, Payam Tabaee , Tabarés‐Seisdedos, Rafael , Tabatabaeizadeh, Seyed‐Amir , Tabche, Celine , Tadele, Afework , Ali, Eman T. , Soodejani, Moslem Taheri , Tajabadi, Shima, Talic, Stella , Talukder, Ashis , Zadeh, Seyed Saeed Tamehri , Tampa, Mircea Ştefan , Tantisattamo, Ekamol , Tariku, Mengistie Kassahun , Tavangar, Seyed Mohammad , Tedla, Mebrahtu G. , Teramoto, Masayuki , Tesfu, Azimeraw Arega , Tharwat, Ismaeel, Tharwat, Samar , Thienemann, Friedrich , Tiruye, Tenaw Yimer , Tleshev, Madi, Tomo, Sojit , Tonelli, Marcello , Touvier, Mathilde , Tran, An Thien, Tran, Thang Huu, Tristan, Christopher Daniel , Tse, Gary , Tseriotis, Vasilis‐Spyridon , Udoakang, Aniefiok John , Ullah, Atta , Ullah, Saeed , Umair, Muhammad, Upadhya, Dinesh , Upadhyay, Era , Usman, Jibrin Sammani , Ozsahin, Dilber Uzun , Uzunçıbuk, Hande , Varghese, Joe , Vasankari, Tommi Juhani , Vellingiri, Balachandar , Venketasubramanian, Narayanaswamy , Verma, Akshaya Kumar , Villalobos-Daniel, Victor Eduardo , Wan, Jin‐Yi , Wang, Cong , Wang, Nelson , Wang, Shaopan , Wang, Shu , Wang, Youxin , Wani, Tanveer A. , Waqar, Ahmed Bilal , Weintraub, Robert G, Wibowo, Yohanes Cakrapradipta, Wicaksana, Anggi Lukman , Wickramasinghe, Dakshitha Praneeth , Wilandika, Angga , Xu, Site , Xu, Suowen , Xu, Xiaoyue , Yadegar, Amirhossein , Yahoo, Saba, Yamagishi, Kazumasa , Yaribeygi, Habib , Yesuf, Subah Abderehim , Yon, Dong Keon , Yonemoto, Naohiro , Yuan, Quan, Yuzbashian, Emad , Zamagni, Giulia , Zawiah, Mohammed , Zeariya, Mohammed G M, Zeru, Eyael M, Zhang, Casper J. P. , Zhong, Claire Chenwen , Zhou, Xiao-Dong, Zhumagaliuly, Abzal , Zoromba, Mohamed Ali , Zumla, Alimuddin I. , Zyoud, Ahed H. , Zyoud, Shaher H. , Mokdad, Ali H. , Murray, Christopher J. L., Roth, Gregory A., Kheirallah, Khalid Ahmed , Saad, Aly M A , Sadeghi, Erfan

Mayo Clinic

JAMA | July 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.8628 | PMID 42525403 Get It

Importance Elevated low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for cardiovascular disease, the leading cause of premature death worldwide. Assessing the LDL-C–related burden is critical for guiding prevention and treatment strategies. Objectives To estimate the global, regional, and national burden of ischemic heart disease and ischemic stroke attributable to elevated LDL-C (relative to 35-54 mg/dL) from 1990 to 2023 and to quantify the contributions of population growth, aging, risk-deleted burden, and exposure changes to burden trends. Design, Setting, and Population This comparative risk assessment, part of the Global Burden of Disease Study 2023, estimated population-level LDL-C exposure and associated health loss in 204 countries and territories. Mean LDL-C levels were estimated using spatiotemporal gaussian process regression based on 806 studies across 161 countries. Relative risks were derived from meta-analyses of 38 randomized clinical trials. Population-attributable fractions for deaths and disability-adjusted life-years (DALYs) were estimated by age and sex for adults aged 25 years or older from 1990 to 2023, with 95% uncertainty intervals. Exposure Population-level LDL-C concentrations. Main Outcomes and Measures Population-attributable fractions, counts, and rates (all ages and age standardized per 100 000) of LDL-C–attributable deaths and DALYs from ischemic heart disease and ischemic stroke, with uncertainty intervals. Results In 2023, elevated LDL-C accounted for 3.6 million deaths (95% uncertainty interval, 2.2-5.4 million; 6.0% of global mortality) and 90.7 million DALYs (95% uncertainty interval, 58.9-123.3 million; 3.2% of DALYs). Although global all-ages rates remained stable, age-standardized death and DALY rates decreased by 45.6% and 39.5%, respectively, since 1990. In 2023, age-standardized LDL-C–attributable DALY rates were highest in Eastern Europe and lowest in high-income Asia-Pacific. One-third of the global LDL-C burden occurred in India and China. Population growth and aging drove the increasing burden, with notable regional disparities in LDL-C exposure and risk-deleted DALY rates shifting toward middle-sociodemographic settings. Conclusions and Relevance Despite declining age-standardized rates, the absolute LDL-C burden has increased since 1990 due to demographic changes and has shifted toward middle-sociodemographic countries. Measurement and surveillance gaps persist. Strengthened prevention, diagnosis, and treatment access strategies are essential to mitigate the health burden of LDL-C.
Intensity-modulated proton therapy versus intensity-modulated photon radiotherapy for locally advanced HPV-positive oropharyngeal squamous cell carcinoma: A systematic review and meta-analysis.
Hassan, Taimoor , Azam, Abdul Rehman , Sawaira, FNU , Gul, Owais, Rehman, Haseeb Ur , Javaid, Muhammad Hassaan, Shahab, Sarim Hassan , Yasir, Muhammad, Jadoon, Ahmed Khan, Zia, Wahab, Khattak, Muhammad Huzaifa, Ahmad, Ashfaq, Gul, Owais, Javaid, Muhammad Hassaan , Arsalan, Muhammad , Jadoon, Ahmed Khan , Khattak, Muhammad Huzaifa , Khalid, Aizaz Anwar

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e18060 Get It

e18060 Background: Intensity-modulated proton therapy (IMPT) has been gaining popularity as a method of treating locally advanced HPV positive oropharyngeal squamous cell carcinoma (OPSCC) due to the ability to reduce the amount of normal tissue that is exposed to radiation but whether or not it will result in better clinical outcomes when compared to intensity-modulated photon radiotherapy (IMRT), is still unknown. We performed a meta-analysis to evaluate the effects of IMPT on both cancer related toxicities and outcomes in comparison to IMRT for patients diagnosed with locally advanced HPV positive OPSCC. Methods: We evaluated all comparative studies that examined the use of IMPT vs. IMRT in stage III-IV HPV positive OPSCC. Using random-effects models, we estimated pooled relative risks (RRs) with 95% CIs for each study's measure of association. The primary outcomes of interest were: weight loss; gastrostomy tube insertion; xerostomia; dysphagia; mucositis; fatigue; locoregional recurrence; and OS. Statistical heterogeneity was assessed via I². Results: In total, there were 4 studies that involved 912 patients. As per these studies, a greater number of patients experienced clinically relevant weight loss when receiving IMPT than when receiving IMRT (RR 1.63, 95% CI 1.17–2.27; p= .004; I²= 0%). Additionally, a comparison of six studies which included a total of 1143 patients indicated that gastrostomy tubes are inserted more often after IMPT (RR 2.9, 95% CI 1.8 – 4.6; p<.00001; I²= 0%). No statistically or clinically significant differences were found regarding other side effects from treatments. In terms of cancer recurrence, there was a greater rate of loco-regional recurrence for those patients who received IMPT as compared to IMRT (RR 1.58, 95% CI 1.26- 1.97; p< .0001; I²= 0%) in three studies which included a total of 592 patients. However, no statistical difference in overall survival was identified between IMPT and IMRT (RR 1.06, 95% CI 0.87- 1.29; p=.56), even though there was significant variability (I²= 87%) in three studies which included a total of 747 patients. Conclusions: In locally advanced HPV positive OPSCC, there were no differences in toxicity profiles from IMPT compared to IMRT, and there were increased rates of weight loss, gastrostomy tube placement, and locoregional recurrence from IMPT compared to IMRT, without any observed survival advantage. This highlights the need for future prospective randomized trials to clarify the role of IMPT in the management of locally advanced HPV positive OPSCC.
Trends and disparities in liver cancer mortality among adults with metabolic disorders in the United States, 1999–2023.
Yasir, Muhammad, Jadoon, Ahmed Khan, Shahab, Sarim Hassan , Sawaira, FNU , Gul, Owais, Naqvi, Syeda Malika , Hayat, Shariq, Saeed, Muhammad Hassan, Javaid, Muhammad Hassaan, Khan, Muhammad, Arshad, Muhammad , Mughees, Muhammad , Arsalan, Muhammad, Jadoon, Ahmed Khan , Gul, Owais, Saeed, Muhammad Hassan , Javaid, Muhammad Hassaan , Khalid, Aizaz Anwar

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e16229 Get It

e16229 Background: Liver cancer is a leading cause of cancer-related mortality worldwide, with rising incidence linked to metabolic disorders. Conditions such as obesity, diabetes mellitus, and metabolic syndrome contribute substantially to non-viral liver carcinogenesis. However, long-term temporal trends and mortality disparities among adults with metabolic disorders in the United States remain incompletely characterized. Methods: Mortality data for liver cancer among adults with metabolic disorders were obtained from the centers for disease control and prevention (CDC) mortality database. Adults aged 25 years and older were included and age-adjusted mortality rates (AAMRs) per 100,000 were calculated. Temporal trends were evaluated using joinpoint regression and average annual percent change (AAPC) with 95% confidence intervals. Results: From 1999–2023, AAMR for liver cancer in adults with metabolic disorders rose from 0.17 to 0.65 per 100,000 in the U.S., with an overall AAPC of 5.95% [95% CI 5.2–6.7]. Men had higher absolute mortality (0.25→0.93; AAPC 5.68%), while women showed a sharper recent rise (0.11→0.41; AAPC 7.08%), peaking at 11.86% annually after 2016. Hispanic/Latino (0.27→0.89; AAPC 6.73%) and Black populations (0.15→0.75; AAPC 6.15%) experienced steady increases, whereas White mortality accelerated post-2011 (AAPC 9.37%). Regionally, the West had highest rates, the South showed highest growth, and Northeast/Midwest had sharp recent increases. Rural mortality overtook urban by 2020 (0.50 vs. 0.48). Most deaths occurred in medical facilities (48.2%) or home (33.1%), with highest state rates in Hawaii (0.56), Texas (0.47), and Rhode Island (0.47). Conclusions: Mortality from liver cancer in adults with metabolic disorders rose sharply in the U.S. since 1999, with accelerating trends and marked disparities by sex, race/ethnicity, region, and urbanization. These findings highlight an urgent need for targeted metabolic risk reduction and equity-focused prevention strategies. Trends in Age-Adjusted Mortality Rates (AAMR) from 1999 to 2023 by demographic and geographic variables. Variable AAMR 1999 (per 100,000) AAMR 2023 (per 100,000) AAPC (95% CI) Overall 0.16 0.64 5.94* (5.22 – 6.67) Males 0.25 0.92 5.67* (4.82 – 6.5) Females 0.11 0.40 7.08* (5.79 – 8.38) White 0.16 0.63 6.12* (5.41 – 6.82) Black 0.15 0.75 6.15* (5.11 – 7.19) Hispanic or Latino 0.27 0.89 6.73* (5.98 – 7.48) Variable AAMR 1999 (per 100,000) AAMR 2020 (per 100,000) AAPC (95% CI) Urban 0.16 0.47 5.38* (4.43 – 6.33) Rural 0.19 0.50 5.73* (4.48 – 6.99) AAPC denotes the average annual percent change; * indicates p < 0.05.
Safety and efficacy of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone in esophageal squamous cell carcinoma: A systematic review and meta-analysis.
Yasir, Muhammad, Sohail, Muhammad, Jadoon, Ahmed Khan, Javaid, Muhammad Hassaan, Hayat, Shariq, Khalid, Aizaz Anwar, Sawaira, FNU , Gul, Owais, Jadoon, Ahmed Khan , Javaid, Muhammad Hassaan , Ahmad, Naveed , Khalid, Aizaz Anwar , Arsalan, Muhammad , Gul, Owais

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e16024 Get It

e16024 Background: Patients with advanced esophageal squamous cell carcinoma (ESCC) continue to have poor outcomes with chemotherapy alone. The addition of PD-L1 inhibitors to first-line chemotherapy has shown encouraging results in individual trials, but the overall magnitude and consistency of benefit across key clinical endpoints have not been fully clarified. To better understand the effects of PD-L1 inhibitors used in combination with chemotherapy, we performed a systematic review and meta-analysis to compare the efficacy and safety of PD-L1-based combination therapies to chemotherapy alone in patients with advanced or metastatic ESCC. Methods: A systematic search of PubMed, Embase, and Scopus identified randomized controlled trials comparing PD-L1 inhibitor plus chemotherapy versus chemotherapy alone in patients with advanced or metastatic ESCC. Three eligible studies met inclusion criteria. We calculated pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS); and pooled risk ratios (RRs) for objective response rate (ORR) and Grade 3-5 treatment-related adverse events (TRAEs) using random effects models. We quantified the heterogeneity among studies using the I² test. Results: Across three randomized trials, the addition of a PD-L1 inhibitor to chemotherapy resulted in a statistically significant and highly consistent survival advantage. OS was longer with combination therapy (HR 0.67, 95% CI 0.60–0.76; p < 0.00001), representing a 33% reduction in the risk of death, with no heterogeneity across studies (I² = 0%). Similarly, PFS was prolonged with combination therapy (HR 0.61, 95% CI 0.55–0.68; p < 0.00001; I² = 0%), corresponding to a 39% reduction in the risk of disease progression or death. Tumor responses occurred at higher frequencies in patients who received PD-L1 inhibitor-based therapy than in patients who received chemotherapy alone (RR = 1.49, 95% CI = 1.35-1.63; p < .00001; I² = 0%). The increased efficacy observed with combination therapy was not accompanied by an increase in severe toxicities. The rates of Grade 3-5 TRAEs were similar between the two groups (RR = 1.06, 95% CI = 0.99-1.13; p = 0.09; I² = 0%). Conclusions: Based on evidence from three randomized trials, the addition of PD-L1 inhibitors to standard chemotherapy improves both survival and response rates in patients with advanced ESCC without an increase in severe treatment related adverse events. Therefore, PD-L1-based combination therapies represent a promising new therapeutic option for patients with advanced ESCC.
Clinician and simulated patient perspectives on ambient AI scribes in psychiatric consultations: a qualitative study
Bokhari, Syed Ali , Usman, Firdous M. , Arshad, Zara, Sudhir, Meghana , Krage, Ralf, Javaid, Syed Fahad , Kashyap, Rahul, Nawaz, Faisal A. , Arshad, Zara , Kashyap, Rahul

Mayo Clinic

Frontiers in Psychiatry | May 28, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fpsyt.2026.1821065 | PMID 42290984 Get It

Background Documentation burden contributes significantly to psychiatric clinician burnout, with psychiatrists spending an average of three hours per workday on administrative tasks rather than direct patient care. While quantitative studies demonstrate that ambient artificial intelligence (AI) scribes reduce workload and improve documentation quality, the experiential perspectives of clinicians and standardized patients (SPs) remain unexplored, particularly in psychiatry where the therapeutic relationship is central to practice. Our aims were to explore clinician and standardized simulated patient perspectives on ambient AI scribes in psychiatric consultations, examining experiences, concerns, and conditions for successful implementation. Methods This study was part of a cross-sectional quantitative simulation study, where qualitative part was planned a-priori. We conducted focus groups with psychiatrists and SPs following a simulation-based crossover study comparing traditional versus AI-assisted documentation. Data were analyzed using Braun and Clarke’s reflexive thematic analysis framework. Results In this focus group session with eight psychiatrists and four SPs, total six themes were identified: (1) Clinical Presence, whereby reduced documentation barriers were perceived to allow more authentic human connection; (2) Liberation from documentation burden, with clinicians describing cognitive and emotional relief beneficial for their mental health; (3) Clinical Competence Amplified, in which clinicians perceived the AI scribe as enhancing practice through intelligent translation to psychiatric terminology and prompting for missed assessments; (4) Calibrating Trust, where participants navigated initial uncertainty while recognizing the importance of human oversight; (5) Privacy, stigma, and psychiatric exceptionalism, highlighting unique consent and confidentiality considerations for psychiatric populations; and (6) Perceptions of an enhanced standard of care, with both groups expressing strong preference for AI-assisted consultations with conditions for adoption. Conclusion In this exploratory simulation-based qualitative study, AI scribes were perceived as having potential to support more present, patient-centered psychiatric consultations by reducing documentation burden. Implementation should be cautious and requires transparent consent processes, clinician training in behavioral adaptations, robust human oversight, specialty-specific templates, and real-world evaluation with patients receiving psychiatric care.
Transulnarversus transradial artery access in patients undergoing cardiac procedures: a systematic review and meta-analysis
Al-Shamari, Mohamed Falah Abdullah, Zreigh, Sofian , Waqas, Daniya, Htet, Yamin , Iqbal, Iqra, Ashraf, Efrah, Javaid, Sana, Farooq, Imshal, Feyisa, Milikyas Abera, Rehman, Mohammad Ebad Ur , Alsubari, Asma’a Munasar Ali, Nashwan, Abdulqadir J. , Mohammad, Ameen Mosa , Ahmad, Adeel, Rehman, Wajeeh Ur , Ahmed, Raheel , Munasar Ali Alsubari, Asma'a , Mosa, Ahmed A. , Htet, Yamin, Iqbal, Iqra, Cheema, Huzaifa Ahmad

Mayo Clinic

Annals of Medicine & Surgery | January 20, 2026 | Volume: 88 | Issue: 2 | Pages: 1806-1814

10.1097/ms9.0000000000004696 | PMID 41675798 Get It

Background: Transradial artery access (TRA) is the favored approach for percutaneous coronary intervention (PCI) and coronary angiography (CAG). However, transulnar artery access (TUA) has emerged as an alternative, particularly when TRA is not feasible. This systematic review and meta-analysis aims to compare the efficacy and safety of TUA versus TRA in patients undergoing PCI and CAG. Methods: From inception to August 2025, a systematic search of electronic databases was conducted. Data were synthesized using a random-effects model, and heterogeneity was assessed using the I 2 statistic. Results: Nine RCTs involving 6089 patients were included. Meta-analysis revealed no significant difference in procedural success between TUA and TRA (RR: 0.93, 95% CI: 0.82–1.06, P = 0.28, I 2 = 99%). Similarly, puncture success rates were comparable (RR: 0.95, 95% CI: 0.91–1.00, P = 0.06, I 2 = 83%). Secondary outcomes showed no significant differences in puncture attempts or hematoma incidence, but TRA was associated with a shorter procedure time (MD: 0.89, 95% CI: 0.27–1.50, P = 0.005). Conclusion: TUA provides a viable alternative to TRA, with similar success rates and complication profiles. However, TRA remains superior in terms of procedure time. Further large-scale RCTs are warranted to confirm these findings and refine clinical guidelines.
Abstract 4370594: Associations Between Chronic Kidney Disease and Inflammatory Biomarkers in the Genetic Epidemiology Network of Arteriopathy Cohort
Javaid, Syed Sarmad , Lirette, Seth T. , Khan, Laibah, Windham, B. Gwen , Butler, Kenneth R. , Tio, Maria Clarissa , Butler, Javed , Hall, Michael E. , Butler, Kenneth R , Lirette, Seth , Khan, Laibah Arshad , Kullo, Iftikhar J. , Rule, Andrew D.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4370594 Get It

Background: Chronic kidney disease (CKD) has been linked to elevated inflammatory biomarkers, yet few studies have evaluated these associations using iothalamate-based measures of kidney function, highlighting the need for further research. Research question: Is CKD associated with elevated inflammatory markers when defined by measured glomerular filtration rate (mGFR) and urinary albumin-to-creatinine ratio (UACR)? Methods: Participants from the Genetic Epidemiology Network of Arteriopathy (GENOA) cohort were included if they had data available for at least one inflammatory marker at visit 2. 17 inflammatory markers were assessed, including C-reactive protein (CRP), interleukin-6 (IL-6), IL-18, tumor necrosis factor receptors 1 and 2 (TNFR1, TNFR2), serum amyloid A, intercellular and vascular adhesion molecules (ICAM, VCAM), E-selectin, P-selectin, monocyte chemoattractant protein (MCP), myeloperoxidase (MPO), receptor for advanced glycation end products (RAGE), matrix metalloproteinases 2 and 9 (MMP-2, MMP-9), and tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1, TIMP-2). Kindey function was assessed using the urinary clearance of iothalamate. CKD was defined as mGFR < 60 mL/min/1.73 m 2 or UACR ≥ 30 mg/g. To further assess whether associations persisted without albuminuria, we also defined CKD solely by mGFR < 60 mL/min/1.73 m 2 . Generalized estimating equations (GEE) were used to assess associations between CKD status and inflammatory markers, accounting for familial clustering. Exponentiated beta coefficients from GEE models were used to present geometric mean (GM) ratios of each biomarker by CKD status, adjusted for demographics, lifestyle factors, cardiovascular risk factors, and medication use. Results: Among 1,010 participants (mean age 61 ± 10 years; 67% women; 48% Black adults), 207 were classified as having CKD. After adjusting for potential confounders, individuals with CKD had significantly higher levels of hsCRP, VCAM, TNFR1, and TNFR2 compared to those without CKD (GM ratios > 1; p < 0.05), while the remaining inflammatory markers showed no significant differences ( Figure 1 ). Importantly, these elevations remained significant when CKD was defined by mGFR alone ( Figure 2 ). Conclusion: Our findings suggest that CKD, defined by mGFR, is associated with specific inflammatory biomarkers, underscoring the need for mechanistic studies to investigate these associations.
Abstract 4369800: Association of Inflammatory Hypertension with Left Ventricular Hypertrophy in Black Adults from the Genetic Epidemiology Network of Arteriopathy Study
Khan, Laibah, Lirette, Seth T. , Javaid, Syed Sarmad , Windham, B. Gwen, Butler, Kenneth R. , Mace, Hunter, Butler, Javed, Hall, Michael E. , Butler, Kenneth R , Lirette, Seth , Khan, Laibah Arshad , Kullo, Iftikhar J. , Blaha, Michael Joseph

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4369800 Get It

Background: Hypertension and systemic inflammation are independently associated with adverse cardiovascular outcomes. While hypertension is a known risk factor for left ventricular (LV) hypertrophy, the role of inflammation in LV structural changes remains unclear. It is also uncertain whether concomitant inflammation and hypertension ("inflammatory hypertension") exacerbate LV hypertrophy. Research Question: Is inflammatory hypertension associated with increased LV mass index (LVMI) compared to hypertension without inflammation? Methods: We analyzed baseline data from Black adults enrolled in the Genetic Epidemiology Network of Arteriopathy (GENOA) cohort in Jackson, Mississippi. Inflammation was defined by high sensitivity C-reactive protein (hsCRP) >3 mg/L, and hypertension as systolic blood pressure (SBP) >130 mmHg. Participants were classified into four groups: noninflammatory-normotensive (reference group), noninflammatory-hypertensive, inflammatory-normotensive, and inflammatory-hypertensive. The primary outcome was LVMI, assessed by echocardiography. Associations between groups and LVMI were evaluated using generalized estimating equations to account for familial clustering and adjusted for covariates including age, sex, education, smoking status, body mass index, number of antihypertensive medications, statin use, cholesterol, and diabetes. Results: Among 1,027 participants (mean age 64 ± 8.5 years; 71% women), baseline LVMI differed by inflammation-hypertension status. Compared with the LVMI in noninflammatory-normotensive cohort (n=108; 74.5 g/m 2 [70.4–78.6]), significantly higher LVMI was observed in noninflammatory-hypertensive (n=343; 83.6 g/m 2 [81.3–85.9], p<0.001) and inflammatory-hypertensive groups (n=497; 84.7 g/m 2 [82.8–86.7], p<0.001). There was no statistically significant difference between inflammatory-hypertensive and noninflammatory-hypertensive groups (84.7 vs 83.6 g/m 2 )(p=0.460). The inflammatory-normotensive cohort also did not differ from the reference group (74.9 g/m 2 [70.2–79.5], p=0.901). Secondary analyses using elevated IL-6 to define inflammation yielded similar findings ( Figure 1 ). Conclusion: In individuals with inflammatory hypertension, hypertension appears to be the primary driver of LV hypertrophy. Further studies in larger, diverse populations are needed to definitively evaluate the potential additive effect of inflammatory hypertension on LV remodeling.
SUN-827 Who Bears the Cost? A Demographic and Geographic Examination of Endocrine Mortality in the U.S.
Kakakhel, Mian Zahid Jan , Cheema, Shamikha , Fatima, Sumaiyah, Noor, Rizwana , Javaid, Hammad , Jawad, Hamna , Haider, Rabbia, Qadeer, Abdul , Khawar, Muneeb , Ashraf, Tuba, Naveed, Farwa , Ahmad, Husnain , Ahmed, Faizan , Fatima, Sumaiyah, Singh, Pranjal Kumar , Ashraf, Tuba, Kirchoff, Robert W.

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.1332 Get It

Abstract Disclosure: M. Kakakhel: None. S. Cheema: None. S. Fatima: None. R. Noor: None. H. Javaid: None. P.K. Singh: None. H. Jawad: None. R. Haider: None. A. Qadeer: None. M. Khawar: None. T. Ashraf: None. F. Naveed: None. H. Ahmad: None. F. Ahmed: None. R. Kirchoff: None. Introduction: The health of a nation is often a reflection of the equity within its systems. Yet, when we examine the United States, one of the most developed nations globally, a concerning picture emerges in the realm of public health significant racial and ethnic disparities in disease outcomes. Among these, endocrine- related mortality, which includes conditions like diabetes, thyroid disorders, and hormonal imbalances, stands as a silent yet significant contributor to health inequities. Using data from the CDC WONDER database, this study seeks to explore these trends in depth, not just to identify the gaps but to shed light on the lived experiences of marginalized communities who bear the brunt of these inequities to pave the way for more equitable healthcare interventions. Methods: This descriptive study analyzes Racial and Ethnic Disparities in Endocrine-Related Mortality in the United States from 1999-2022, utilizing data from CDC Wonder database. We searched the Center for Disease Control database from 1999 to 2022 for mortality statistics with an underlying cause of death. The age-adjusted mortality rate (AAMR) was calculated per 1,000,000 deaths. We evaluated the AAMR using demographic variables such as race/ethnicity, geographic density, gender, age (25 or above), place of death, and the US Census Region. Temporal trends were assessed using Joinpoint regression software. Mortality rates by age, demographics, and place of death were examined. Statistical analysis calculated endocrine-related mortality rates and trends, with findings deemed significant at P &lt; 0. 05. Results: Between the years 1999 to 2022, 837203 deaths were recorded to be caused by endocrine-related disorders. An overall rising mortality trend from 1999-2022 among all races and ethnicities is noted, except in Asian or Pacific Islander, Black or African American, and Hispanic patients, which shows a rise till 2020 followed by fall in age-adjusted mortality rates (AAMR) in 2022. A significant dip in mortality rate was seen in 2017 in all racial and ethnic groups. American Indian or Alaska Natives showed highest AAMR (181.87, 95% CI 178.06-185.69) followed by Black or African Americans (149.78, 95% CI 148.9-150.64), Hispanic or Latinos (112.33, 95% CI 111.59-113.07), Whites (94.31, 95% CI 66.6-68.25), Asian or Pacific Islanders (67.45, 95% CI 66.6-68.25). American Indians or Alaska Natives exhibit the steepest rise over time (APC -0.32 TO 8.85) from 1999-2022. Conclusions: Mortality due to endocrine-related disorders has dramatically increased over time. Significant disparities have been noted among different races and ethnic groups, with the highest rate among Americans and the lowest among Asians. This underscores the need for targeted interventions for specific racial groups to reduce the mortality burden of endocrine-related diseases. Presentation: Sunday, July 13, 2025
Comparative efficacy of PARP inhibitors in BRCA mutated HER2-negative breast cancer: A systematic review and network meta-analysis of randomized controlled trials.
Zaheer, Amna , Bakry, Niveen S. , Muneer, Muneeb Ahmad , Kashif, Muhammad Arham Bin , Javaid, Hammad , Ismail, Areeba, Bist, Anil , Rath, Shree , Afridi, Abdullah , Kaur, Anmol , Cheema, Shamikha , Panjwani, Shaliza, Bukhari, Syed Mohsin Raza, Shamim, Urooj, Patan, Shajadi, Dey, Debankur , Bakry, Nourhan Saeed, Rath, Shree , Bukhari, Syed Mohsin Raza , Marsool, Mohammed Dheyaa Marsool

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e13162 Get It

e13162 Background: BRCA1/2 mutations impair homologous recombination repair, forcing cancer cells to rely on alternative DNA repair pathways, such as those mediated by poly(ADP-ribose) polymerase (PARP). PARP inhibitors (PARPis), like iniparib, olaparib, talazoparib, niraparib, and veliparib, exploit this dependency, inducing lethality in cells of BRCA-mutated, HER2-negative breast cancers (BRCAm, HER2-BC). Only 2 PARPis, talazoparib and olaparib, are FDA-approved for BRCAm, HER2-BC. However, the treatment with the highest efficacy remains unclear. We conducted a network meta-analysis (NMA) of randomised controlled trials (RCTs) to compare the efficacy of PARPis in treating BRCAm, HER2-BC. Methods: We systematically searched PubMed, Cochrane CENTRAL, SCOPUS, and ClinicalTrials.gov (up to December 2024) for randomized controlled trials (RCTs) following PRISMA-NMA guidelines. Primary outcome was overall survival(OS), with hazard ratios (HRs) and 95% confidence intervals (CIs). Secondary outcome was progression-free survival (PFS). Survival times were converted to HRs under the assumption of exponential distribution. Standard of care (SOC) was defined as taxane/anthracycline-based regimens with additional platinum-based chemotherapy. Physician's choice chemotherapy (PCT) included capecitabine, eribulin, gemcitabine, or vinorelbine. A frequentist approach with random-effects modeling was used to pool estimates, and P-scores ranked treatment efficacy. Heterogeneity and inconsistency were assessed using τ², I², and Q-statistics. Analyses were conducted in R version 4.4.1. Results: 8 studies including 4432 participants incorporating 8 pairwise comparisons and 7 treatments were analyzed for OS. Compared to SOC (reference), HRs of OS were significantly reduced with talazoparib+SOC (HR = 0.49, 95% CI: 0.32–0.74; P = 0.64), olaparib+SOC (HR = 0.46, 95% CI: 0.36–0.59; P = 0.69), niraparib+SOC (HR = 0.44, 95% CI: 0.26–0.76; P = 0.76), and veliparib+SOC (HR = 0.38, 95% CI: 0.29–0.48; P = 0.91). No heterogeneity or inconsistency was detected (τ² = 0; I² = 0; Q = 1.27, p = 0.53). For PFS, iniparib/gemcitabine, talazoparib, olaparib, and niraparib showed significant reduction in HR with increasing order of P-scores, in combination with SOC. Conclusions: Veliparib combined with SOC showed the highest OS improvement, while niraparib ranked highest for PFS, followed by talazoparib and olaparib. Further trials are needed to confirm these findings and refine treatment strategies for BRCAm, HER2-BC.